You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Integrated molecular diagnostic system for the point-of-care


    DESCRIPTION (provided by applicant): This STTR-AT-NIAID seeks to develop an integrated nucleic acid system based on research done by Catherine Klapperich's laboratory at Boston University. The BU lab-on-a-chip includes a micro solid phase extraction (lt SPE) column, flap valves and hydrophobic vents to gate fluid movements through micro channels, and multiple reaction chambers for experimenta ...

    STTR Phase I 2011 Department of Health and Human Services
  2. Isolation of functional IgGs in the cytoplasm of a novel E. coli expression host

    SBC: NEW ENGLAND BIOLABS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Monoclonal antibodies (mAbs) hold great promise in human health with applications ranging from therapeutic agents that target cancer cells, to diagnostic biomarkers that can detect trace levels of a given antigen. Thispromise is best reflected in global sales of antibodies which reached nearly 31 billion in 2007 and future sales predicted to reach 56 billion ...

    STTR Phase I 2011 Department of Health and Human Services

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Infections associated with medical devices can be serious and even fatal. Catheter colonization and production of a biofilm on the surface of a catheter shortly after implantation are normally the prelude for infections. A number of antimicrobial-treated catheters have been developed to combat these infections, however, many of them have limited clinical effica ...

    STTR Phase I 2011 Department of Health and Human Services
  4. A vaccine against Clostridium difficile infections


    DESCRIPTION (provided by applicant): In this proposal we lay out a comprehensive research plan to evaluate our vaccination strategies targeting Clostridium difficile to prevent or treat infections. With the emergence of highly antibiotic-resistant bacterial strains, new approaches for combating bacterial infections are desperately needed. In this research proposal, Sorrento Therapeutics Inc. (STI ...

    STTR Phase I 2011 Department of Health and Human Services
  5. Developing small molecule therapeutics for lupus

    SBC: Biomedical Research Models, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Systemic lupus erythematosus (SLE) affects ~ 2 million Americans with devastating impact on multiple organs, especially the skin, joints, kidney, and brain. Therapeutic strategies for lupus are largely palliative orimmunosuppressive with serious toxicities. No new drugs for SLE have been approved in decades. Thus, novel therapeutic approaches to lupus - par ...

    STTR Phase I 2011 Department of Health and Human Services
  6. A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors


    DESCRIPTION (provided by applicant): Cancer is America's second leading cause of death. Many approved cancer drugs, such as bortezomib (Velcade), are cytotoxic agents that kill normal cells as well as tumor cells. Therapeutic benefit depends on tumor cellsbeing more sensitive than normal cells, thereby allowing clinical responses to be achieved at relatively safe drug doses; however, damage t ...

    STTR Phase I 2011 Department of Health and Human Services
  7. Liposomal Nicotine Vaccine Development

    SBC: Molecular Express Inc            Topic: NIDA

    DESCRIPTION (provided by applicant): In response to RFA-DA-11-004, we propose in this STTR Phase I application to develop and test a nicotine vaccine utilizing a chemical derivative of the drug, or hapten, coupled to an immunostimulatory, adjuvant-containing liposome. The current approach to curbing nicotine addiction is the use of over the counter nicotine replacement products, but this approach ...

    STTR Phase I 2011 Department of Health and Human Services
  8. Developing Novel Dual CRF-R1/Orexin-1 Receptor Antagonists for Tobacco Dependence

    SBC: HAGER BIOSCIENCES, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): Tobacco use is now recognized as the single most responsible cause of avoidable death worldwide representing approximately 10% of all deaths globally. Directly or indirectly, long term tobacco use has been implicated incomplex major health disorders such as cancer, stroke, cardiovascular diseases, and mental disorders. In the USA alone, 30% of all cancer deaths ...

    STTR Phase I 2011 Department of Health and Human Services
  9. In vivo and in vitro tools to target CHRNA5 for smoking cessation.

    SBC: OPHIDION, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Nicotine is one of the most heavily used addictive drugs and accounts for 90% of lung cancer cases in the U.S. Recent studies have implicated a specialized receptor class binding to nicotine, the CHRNA5 gene, which encodes the a5 subunit of the nicotinic receptor, as a contributing factor in the risk towards nicotine dependence. This, along with animal studies ...

    STTR Phase I 2011 Department of Health and Human Services
  10. Bi-frequency PC-MUT Co-linear Array for Ophthalmic Imaging

    SBC: Blatek, Inc.            Topic: NEI

    DESCRIPTION (provided by applicant): Ultrasound imaging of the anterior segment, posterior segment and the full lens contour is important in diagnosis of glaucoma, cataracts, etc. eye disease, eye surgery guidance and post surgery assessment. High resolution, large field of depth and rapid electronic scanning are necessary to obtain accurate images of eye as a whole. Blatek, NCSU and USC team ...

    STTR Phase I 2011 Department of Health and Human Services
US Flag An Official Website of the United States Government